CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics said the final gapfill payment rate of $854 for both tests is an increase from the preliminary gapfill ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...
TipRanks on MSN
GENinCode partners with Sohin Genetics to distribute heart disease risk test in Mexico
An announcement from GENinCode UK Ltd. ( ($GB:GENI) ) is now available. GENinCode has announced a collaboration with Sohin Genetics in Mexico to ...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (CDIO) (Nasdaq: CDIO), an AI-powered ...
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease AGEPHA Pharma will supply LODOCO® ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback